Enoxaparin for VTE Prophylaxis in ARDS

Standard Prophylactic Approach

• The American Society of Hematology recommends universal thromboprophylaxis for all ARDS patients unless absolute contraindications exist, such as active major bleeding or severe thrombocytopenia with platelet count <50,000/μL 1, 2, 4
• ARDS patients face a multifold higher risk for VTE, particularly pulmonary embolism, compared to general medical patients, supporting the use of thromboprophylaxis 1, 5

Risk-Stratified Dose Escalation

• The guidelines support escalating to intermediate-dose prophylaxis for high-risk features, including obesity (BMI >30 kg/m²), severe hypercoagulability (D-dimer >6 times upper limit of normal), or sepsis-induced coagulopathy score ≥4 1, 2, 4, 3
• Escalate to enoxaparin 40 mg twice daily or 0.5 mg/kg twice daily for patients with high-risk features, such as obesity (BMI >30 kg/m²) 1, 2, 4, 6, 3

Multimodal Prophylaxis Strategy

• Combine pharmacologic prophylaxis with mechanical methods, such as intermittent pneumatic compression devices, in all ARDS patients 1, 2, 4, 3
• Add intermittent pneumatic compression devices to enoxaparin for all critically ill, immobile ARDS patients 1, 2, 4, 3

Critical Dose Adjustments

• For creatinine clearance <30 mL/min, switch to unfractionated heparin 5,000 units subcutaneously every 8-12 hours, as enoxaparin clearance is reduced by 44% in severe renal impairment, increasing bleeding risk nearly 4-fold without adjustment 1, 2, 3
• Monitor platelet count every 2-3 days from day 4 to day 14 to screen for heparin-induced thrombocytopenia 7, 6

Duration of Prophylaxis

• Continue enoxaparin prophylaxis throughout the entire ICU and hospital stay, as recommended by the American Society of Hematology guidelines 3
• The American Society of Hematology guidelines recommend against extending prophylaxis beyond hospital discharge in general medical patients due to increased major bleeding risk without clear mortality benefit 8

What NOT to Do

• Do not use therapeutic-dose anticoagulation for primary prophylaxis in ARDS patients without confirmed VTE, as efficacy and safety data are limited and ongoing trials have not yet established benefit 1, 2, 4, 3
• Do not use standard prophylactic dosing in obese patients without dose adjustment, as this leads to subtherapeutic anticoagulation 1, 2, 4, 6

Evidence Quality and Nuances

• The recommendations for standard prophylactic dosing are well-established, supported by multiple high-quality guidelines, including the Journal of Thrombosis and Haemostasis 1, 2, 4, 3
• Enoxaparin offers several advantages over unfractionated heparin, including better bioavailability, longer half-life, more predictable anticoagulation, and lower risk of heparin-induced thrombocytopenia 6